PYC Therapeutics Ltd (ASX: PYC) shares are back on the move today, extending what has already been a strong week for the clinical-stage biotech.
At the time of writing, the PYC share price has climbed 5.65% to $1.215, building on a 14% gain over the past week.
The latest rise keeps the stock well above last week's pullback low of $1.05 and suggests buying momentum is rebuilding.
Here's what investors are focusing on.
Image source: Getty Images
Lead ADOA program moves into its next study phase
According to the release, PYC has been cleared to move its lead ADOA drug candidate, PYC-001, into the next trial stage. This followed a safety committee review of early patient data from the 60-microgram dose.
The company can now begin testing repeated 60 microgram doses in patients. This will sit alongside the 10 and 30 microgram groups already being studied in the Myrtle trial.
The trial targets Autosomal Dominant Optic Atrophy (ADOA), a rare inherited eye condition that gradually causes vision loss.
There are currently no approved treatments for the disease.
Management said new data from the study is expected across 2026 and 2027, which gives investors a clearer timeline for the next major updates.
Why this milestone is getting attention
Clinical biotech stocks are often valued on steady trial progress and reduced development risk, not short-term revenue.
The key point here is that the program is moving into higher dosing levels without safety issues serious enough to delay the study.
That keeps the trial on schedule and can support sentiment ahead of future efficacy data.
Because this is a first-of-its-kind RNA therapy targeting the OPA1 mutation, each successful step helps support the program's progress into larger studies.
A OPA1 mutation is a genetic fault that damages the optic nerve over time, leading to progressive vision loss in people with ADOA.
The company is already funded into 2030 following its February capital raise, which should ease concerns about another raise in the near-term.
Foolish Takeaway
PYC's latest gain looks linked to another positive step in its lead blindness program.
The company is still pre-revenue, so future trial results are likely to remain the biggest driver of the share price.
In my view, steady safety progress is a good sign that the lead study is moving the right way. It also helps reduce some of the usual risks around early-stage biotech trials.
With more data expected through 2026, the shares could continue responding to each clinical update.
